The price-to-earnings ratio for Conmed Corp. (NYSE: CNMD) is 34.32x, which is above its average ratio. Moreover, the 36-month beta value for CNMD is 1.36. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for CNMD is 30.55M and currently, short sellers hold a 13.31% of that float. On April 25, 2024, CNMD’s average trading volume was 572.79K shares.
CNMD) stock’s latest price update
The stock of Conmed Corp. (NYSE: CNMD) has decreased by -1.82 when compared to last closing price of 71.31. Despite this, the company has experienced a -3.78% fall in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-24 that The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CNMD’s Market Performance
Conmed Corp. (CNMD) has experienced a -3.78% fall in stock performance for the past week, with a -8.67% drop in the past month, and a -23.13% drop in the past quarter. The volatility ratio for the week is 2.75%, and the volatility levels for the past 30 days are at 2.83% for CNMD. The simple moving average for the last 20 days is -8.47% for CNMD stock, with a simple moving average of -29.84% for the last 200 days.
Analysts’ Opinion of CNMD
Many brokerage firms have already submitted their reports for CNMD stocks, with Needham repeating the rating for CNMD by listing it as a “Buy.” The predicted price for CNMD in the upcoming period, according to Needham is $129 based on the research report published on February 01, 2024 of the current year 2024.
CL King, on the other hand, stated in their research note that they expect to see CNMD reach a price target of $140. The rating they have provided for CNMD stocks is “Buy” according to the report published on May 22nd, 2023.
KeyBanc Capital Markets gave a rating of “Overweight” to CNMD, setting the target price at $124 in the report published on March 27th of the previous year.
CNMD Trading at -11.70% from the 50-Day Moving Average
After a stumble in the market that brought CNMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.44% of loss for the given period.
Volatility was left at 2.83%, however, over the last 30 days, the volatility rate increased by 2.75%, as shares sank -9.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.13% lower at present.
During the last 5 trading sessions, CNMD fell by -3.78%, which changed the moving average for the period of 200-days by -47.63% in comparison to the 20-day moving average, which settled at $76.14. In addition, Conmed Corp. saw -36.07% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CNMD starting from Peters Stanley W III, who sale 2,300 shares at the price of $109.93 back on Dec 04 ’23. After this action, Peters Stanley W III now owns 63 shares of Conmed Corp., valued at $252,833 using the latest closing price.
Peters Stanley W III, the President AS and AET of Conmed Corp., sale 1,200 shares at $102.39 during a trade that took place back on Nov 07 ’23, which means that Peters Stanley W III is holding 63 shares at $122,874 based on the most recent closing price.
Stock Fundamentals for CNMD
Current profitability levels for the company are sitting at:
- 0.08 for the present operating margin
- 0.55 for the gross margin
The net margin for Conmed Corp. stands at 0.05. The total capital return value is set at 0.05. Equity return is now at value 8.16, with 2.80 for asset returns.
Based on Conmed Corp. (CNMD), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at 0.13. The debt to equity ratio resting at 1.17. The interest coverage ratio of the stock is 2.4.
Currently, EBITDA for the company is 182.19 million with net debt to EBITDA at 7.36. When we switch over and look at the enterprise to sales, we see a ratio of 2.51. The receivables turnover for the company is 5.14for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.98.
Conclusion
To wrap up, the performance of Conmed Corp. (CNMD) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
